HSBC recently lowered its price target on Zoetis Inc. (ZTS) from $180 to $140, while maintaining a Buy rating. Barclays also initiated coverage on ZTS with an Equal-Weight rating and a $136 price target. The pharmaceutical company has struggled in 2025, down 28% year-to-date. Analysts have a Moderate Buy rating on ZTS with an average price target of $161.03, indicating a 38% upside potential. Despite its potential, some believe other AI stocks offer better upside with less risk.

Read more at Yahoo Finance: HSBC Cuts Zoetis Inc. (ZTS)’s Price Target To $140 From $180, Keeps Buy Rating